AL Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
AL
Amyloidosis Overview
AL
amyloidosis, also known as Immunoglobulinic amyloidosis or primary amyloidosis,
results from the extracellular deposition of fibrils made up of monoclonal
immunoglobulin (Ig) light chain (LC), secreted by a small plasma cell clone
that exerts organ toxicity causing organ dysfunction and eventually death. The
alteration in the secondary or tertiary structure of an abnormal monoclonal LC
results in unstable conformation is the event in the development of Al
amyloidosis. The conformational change causes abnormal folding of the LC, which
is rich in β leaves and assembles into monomers that stack together to form
amyloid fibrils. The typical clinical symptoms are asthenia and dyspnoea, which
account for delayed diagnosis. Renal manifestations affect two third of
patients, and heart involvement presents in more than 50% of patients as the
most severe complication. The combination of Daratumumab, Cyclophosphamide,
Bortezomib, and Dexamethasone (Dara-VCd) is currently the novel and preferred
standard of care for newly diagnosed patients with AL amyloidosis.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment